A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

This study looks at how well men in France stick to their prescribed apalutamide treatment for prostate cancer that has spread to other parts of the body but still responds to hormone therapy. Researchers will track whether patients take their medication as directed and how it affects their quality of life. **You may be eligible if...** - You are male and at least 18 years old - You have been diagnosed with prostate cancer that has spread (metastatic) and still responds to hormone treatment - Your doctor has decided to start you on apalutamide plus hormone therapy - You can read and speak French - You have had a PSA blood test before starting treatment **You may NOT be eligible if...** - You have already received or are currently taking apalutamide or similar prostate cancer drugs - You received hormone therapy for this cancer for more than 4 months before starting apalutamide - Your cancer has already stopped responding to hormone therapy - You are enrolled in another interventional clinical trial - You are under legal guardianship or judicial protection Talk to your doctor to see if this trial is right for you.